Suppr超能文献

多剂量口服阿奇霉素混悬液后在儿科患者中的药代动力学

Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension.

作者信息

Nahata M C, Koranyi K I, Gadgil S D, Hilligoss D M, Fouda H G, Gardner M J

机构信息

College of Pharmacy, Ohio State University, Columbus 43210.

出版信息

Antimicrob Agents Chemother. 1993 Feb;37(2):314-6. doi: 10.1128/AAC.37.2.314.

Abstract

Azithromycin is an azalide antibiotic. On the basis of data in adults, azithromycin appears to have a greater distribution into tissues, a longer elimination half-life, and a lower incidence of adverse effects than the macrolide antibiotic erythromycin. However, little about the pharmacokinetics of azithromycin in children is known. The objective of our study was to characterize the pharmacokinetics of azithromycin after oral administration of multiple doses of suspension to children with streptococcal pharyngitis. Fourteen children (6 to 15 years of age) received a single oral dose of 10 mg of azithromycin per kg of body weight on day 1 followed by single daily doses of 5 mg/kg on days 2 to 5. Each child fasted overnight before receiving the final dose on day 5. Blood samples were collected at 0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 h after this last dose. Concentrations of azithromycin in serum were measured by a specific high-performance liquid chromatography-mass spectrometry method. The mean +/- standard deviation for maximum concentration of drug in serum, time to maximum concentration of drug in serum, and area under the curve (0 to 24 h) were 383 +/- 142 ng/ml, 2.4 +/- 1.1 h, and 3,109 +/- 1,033 ng.h/ml, respectively. Concentrations in serum at 0 h (predose) and at 24, 48, and 72 h after the final dose were 67 +/- 31, 64 +/- 24, 41 +/- 17, and 29 +/- 14 ng/ml, respectively. Thus, once-daily administration of azithromycin resulted in sustained systemic exposure to the drug.

摘要

阿奇霉素是一种氮杂内酯类抗生素。根据成人数据,与大环内酯类抗生素红霉素相比,阿奇霉素似乎在组织中的分布更广、消除半衰期更长且不良反应发生率更低。然而,关于阿奇霉素在儿童体内的药代动力学情况却知之甚少。我们研究的目的是对患有链球菌性咽炎的儿童口服多剂量混悬液后阿奇霉素的药代动力学特征进行描述。14名儿童(6至15岁)在第1天接受单次口服剂量为每千克体重10毫克的阿奇霉素,随后在第2至5天每天接受单次剂量为5毫克/千克。在第5天接受最后一剂之前,每个儿童均禁食过夜。在最后一剂后的0、0.5、1、2、4、6、8、12、24、48和72小时采集血样。采用特定的高效液相色谱-质谱法测定血清中阿奇霉素的浓度。血清中药物最大浓度、药物达到最大浓度的时间以及曲线下面积(0至24小时)的平均值±标准差分别为383±142纳克/毫升、2.4±1.1小时和3109±1033纳克·小时/毫升。最后一剂后0小时(给药前)以及24、48和72小时血清中的浓度分别为67±31、64±24、41±17和29±14纳克/毫升。因此,阿奇霉素每日一次给药导致药物在体内持续暴露。

相似文献

1
Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension.
Antimicrob Agents Chemother. 1993 Feb;37(2):314-6. doi: 10.1128/AAC.37.2.314.
2
Pharmacokinetics of azithromycin in pediatric patients with acute otitis media.
Antimicrob Agents Chemother. 1995 Aug;39(8):1875-7. doi: 10.1128/AAC.39.8.1875.
3
Pharmacokinetics of loracarbef in pediatric patients.
Eur J Drug Metab Pharmacokinet. 1992 Jul-Sep;17(3):201-4. doi: 10.1007/BF03190146.
4
Macrolides in the management of streptococcal pharyngitis/tonsillitis.
Pediatr Infect Dis J. 1997 Apr;16(4):444-8. doi: 10.1097/00006454-199704000-00028.
5
The pharmacokinetics of azithromycin and their clinical significance.
Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):807-12. doi: 10.1007/BF01975832.
6
Pharmacokinetics of azithromycin in rats and dogs.
J Antimicrob Chemother. 1990 Jan;25 Suppl A:49-60. doi: 10.1093/jac/25.suppl_a.49.
7
The pharmacokinetics of azithromycin in human serum and tissues.
J Antimicrob Chemother. 1990 Jan;25 Suppl A:73-82. doi: 10.1093/jac/25.suppl_a.73.
8
Concentrations of azithromycin in human tonsillar tissue.
Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):853-6. doi: 10.1007/BF01975840.
10
Pharmacokinetics of azithromycin after single oral dosing of experimental animals.
Biopharm Drug Dispos. 1991 Oct;12(7):505-14. doi: 10.1002/bdd.2510120704.

引用本文的文献

2
Pharmacokinetics and Histotoxic Profile of a Novel Azithromycin-Loaded Lipid-Based Nanoformulation.
AAPS PharmSciTech. 2024 Jul 9;25(6):157. doi: 10.1208/s12249-024-02861-3.
3
Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants.
Biomedicines. 2023 Mar 17;11(3):940. doi: 10.3390/biomedicines11030940.
4
A comparison of different methods for the first-in-pediatric dose selection.
J Clin Transl Res. 2022 Sep 7;8(5):369-381. eCollection 2022 Oct 31.
5
Mechanism of action, resistance, synergism, and clinical implications of azithromycin.
J Clin Lab Anal. 2022 Jun;36(6):e24427. doi: 10.1002/jcla.24427. Epub 2022 Apr 21.
6
Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis.
J Cyst Fibros. 2021 Sep;20(5):772-778. doi: 10.1016/j.jcf.2021.04.011. Epub 2021 May 21.
7
Ensuring safe and effective medication use in pediatric patients.
J Pediatr Pharmacol Ther. 2014 Jan;19(1):4-9. doi: 10.5863/1551-6776-19.1.4.

本文引用的文献

1
Comparative in vitro potencies of nine new macrolides.
Drugs Exp Clin Res. 1988;14(7):445-51.
2
New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.
Antimicrob Agents Chemother. 1989 Sep;33(9):1419-22. doi: 10.1128/AAC.33.9.1419.
3
New directions for macrolide antibiotics: structural modifications and in vitro activity.
Antimicrob Agents Chemother. 1989 Sep;33(9):1413-8. doi: 10.1128/AAC.33.9.1413.
4
The pharmacokinetics of azithromycin in human serum and tissues.
J Antimicrob Chemother. 1990 Jan;25 Suppl A:73-82. doi: 10.1093/jac/25.suppl_a.73.
6
High-performance liquid chromatographic assay with electrochemical detection for azithromycin in serum and tissues.
J Chromatogr. 1991 Apr 19;565(1-2):321-37. doi: 10.1016/0378-4347(91)80393-q.
8
The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin.
Ann Pharmacother. 1992 Jan;26(1):46-55. doi: 10.1177/106002809202600112.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验